Literature DB >> 24120021

Comparing disease activity indices in ulcerative colitis.

A J Walsh1, A Ghosh2, A O Brain3, O Buchel4, D Burger5, S Thomas6, L White3, G S Collins7, S Keshav3, S P L Travis8.   

Abstract

BACKGROUND: Comparisons between disease activity indices for ulcerative colitis (UC) are few. This study evaluates three indices, to determine the potential impact of inter-observer variation on clinical trial recruitment or outcome as well as their clinical relevance.
METHODS: One hundred patients with UC were prospectively evaluated, each by four specialists, followed by videosigmoidoscopy, which was later scored by each specialist. The Simple Clinical Colitis Activity (SCCAI), Mayo Clinic and Seo indices were compared by assigning a disease activity category from published thresholds for remission, mild, moderate and severe activity. Inter-observer variation was evaluated using Kappa statistics and its effect for each patient on recruitment and outcome measures for representative clinical trials calculated. Clinical relevance was assessed by comparing an independently assigned clinical category, taking all information into account as if in clinic, with the disease activity assigned by the indices.
RESULTS: Inter-observer agreement for SCCAI (κ=0.75, 95% CI 0.70-0.81), Mayo Clinic (κ=0.72, 95% CI 0.67-0.78) and Seo (κ=0.89, 95% CI 0.83-0.95) indices was good or very good as was the agreement for rectal bleeding (κ=0.77) and stool frequency (κ=0.90). Endoscopy in the Mayo Clinic index had the greatest variation (κ=0.38). Inter-observer variation alone would have excluded up to 1 in 5 patients from recruitment or remission criteria in representative trials. Categorisation by the SCCAI, Mayo Clinic and Seo indices agreed with the independently assigned clinical category in 61%, 67% and 47% of cases respectively.
CONCLUSIONS: Trial recruitment and outcome measures are affected by inter-observer variation in UC activity indices, and endoscopic scoring was the component most susceptible to variation.
© 2013.

Entities:  

Keywords:  Activity index; Clinical trial design; Endoscopy; Mayo Clinic index; Ulcerative colitis

Mesh:

Year:  2013        PMID: 24120021     DOI: 10.1016/j.crohns.2013.09.010

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  23 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

2.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

Review 3.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

4.  A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Michael D Kappelman; Millie D Long; Donna M Evon; Christopher F Martin; Robert S Sandler
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

5.  Activation, Deficiency, and Reduced IFN-γ Production of Mucosal-Associated Invariant T Cells in Patients with Inflammatory Bowel Disease.

Authors:  Jae Kyun Ju; Young-Nan Cho; Ki-Jeong Park; Han Deok Kwak; Hye-Mi Jin; Seon-Young Park; Hyun Soo Kim; Seung-Jung Kee; Yong-Wook Park
Journal:  J Innate Immun       Date:  2020-06-12       Impact factor: 7.349

6.  Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.

Authors:  Christopher Ma; Jenny Jeyarajah; Leonardo Guizzetti; Claire E Parker; Siddharth Singh; Parambir S Dulai; Geert R D'Haens; William J Sandborn; Brian G Feagan; Vipul Jairath
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-03       Impact factor: 11.382

7.  Opportunistic detection of Fusobacterium nucleatum as a marker for the early gut microbial dysbiosis.

Authors:  Ji-Won Huh; Tae-Young Roh
Journal:  BMC Microbiol       Date:  2020-07-13       Impact factor: 3.605

8.  The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

Authors:  Simon P L Travis; Dan Schnell; Brian G Feagan; Maria T Abreu; Douglas G Altman; Stephen B Hanauer; Piotr Krzeski; Gary R Lichtenstein; Philippe R Marteau; Jean-Yves Mary; Walter Reinisch; Bruce E Sands; Patrick Schnell; Bruce R Yacyshyn; Jean-Frédéric Colombel; Christian A Bernhardt; William J Sandborn
Journal:  J Crohns Colitis       Date:  2015-05-08       Impact factor: 9.071

Review 9.  Endoscopic Disease Activity in Inflammatory Bowel Disease.

Authors:  Shara Nguyen Ket; Rebecca Palmer; Simon Travis
Journal:  Curr Gastroenterol Rep       Date:  2015-12

10.  Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis.

Authors:  Basavaraj Kerur; Heather J Litman; Julia Bender Stern; Sarah Weber; Jenifer R Lightdale; Paul A Rufo; Athos Bousvaros
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.